Table 3.

Association of osteopontin expression with relapse-free survival in studies 1 and 2

Study 1 raw dataStudy 1 adjusted for age, sex, and site of tumorStudy 1 adjusted additionally for histologic measuresStudy 2 study raw dataStudy 2 adjusted for age, sex, and site of tumorStudy 2 adjusted for age, sex, site of tumor, and SNB statusStudy 2 adjusted additionally for histologic measuresStudy 2 adjusted additionally for histologic measures and SNB status
Mean (SD) signal relapsers5,396 (2,503)5,031 (2,385)4,552 (2,074)5,812 (2,752)6,130 (2,701)4,103 (2,619)5,907 (2,537)4,575 (2,485)
Mean (SD) signal nonrelapsers3,476 (2,255)3,060 (2,248)3,180 (2,127)4,411 (2,818)4,533 (2,775)3,227 (2,622)4,988 (2,460)4,051 (2,389)
Fold change1.551.641.431.321.351.271.181.13
Hazard ratio (95% confidence interval)3.17 (1.91-5.26)3.33 (1.96-5.67)2.76 (1.49-5.10)1.60 (1.13-2.27)1.67 (1.16-2.40)1.40 (0.97-2.03)1.24 (0.81-1.90)1.11 (0.73-1.69)
Significance value2.11 × 10−69.19 × 10−60.0010.0060.0060.070.320.62

NOTE: The raw data are presented in column 1. The association was adjusted for sex, patient age, and tumor site (as known predictors of outcome) in column 2 (mean signal values are presented for a 45-year-old female with a tumor on her leg). In column 3, further adjustment is made for known histologic predictors of outcome: Breslow thickness, mitotic rate, and ulceration (mean signal values are presented for a 45-year-old female patient with a nonulcerated tumor on her leg, which has a Breslow thickness of 2.5 mm and a mitotic rate of 1-6/mm2). Study 2 analyses are similarly presented with mean signal values adjusted for SNB status.